Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.47 |
| ▸ | MPL | P40238 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30310723 | 0.79 | XDH (0.47) | MAPTCYP1A2 | |
| SCHEMBL7673791 | 0.79 | XDH (0.47) | MAPTCYP1A2 | |
| SCHEMBL6437711 | 0.76 | RHEB (0.61) | RHEBMAPTKMT2AMEN1CASP3 | |
| SCHEMBL16534700 | 0.73 | PTGS1 (0.49) | RHEBMAPTKMT2AMEN1CASP3 | |
| SCHEMBL15567474 | 0.72 | PARP1 (0.57) | MAPTKMT2AMEN1MAPK13ALOX5 | |
| SCHEMBL28580125 | 0.70 | RAB9A (0.61) | RHEBMAPTKMT2AMEN1CASP3 | |
| SCHEMBL6710661 | 0.70 | HDAC6 (0.55) | RHEBMAPTKMT2AMEN1CASP3 | |
| SCHEMBL167256 | 0.70 | HDAC6 (0.52) | MAPTKMT2AMEN1MAPK13ALOX5 | |
| SCHEMBL31710883 | 0.70 | PTGDR2 (0.48) | RHEBCASP3SENP7ALDH1A1SMN1; SMN2 | |
| SCHEMBL16534791 | 0.69 | PTGS1 (0.48) | RHEBMAPTKMT2AMEN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816542-B2 | Compounds and compositions as TPO mimetics | IRM LLC (BM) | 2010-10-19 | — | — | US | disclosed |
| US-7816542-B2 | Compounds and compositions as TPO mimetics | IRM LLC (BM) | 2010-10-19 | — | — | US | disclosed |
| US-7816542-B2 | Compounds and compositions as TPO mimetics | IRM LLC (BM) | 2010-10-19 | — | — | US | disclosed |
| US-20080194668-A1 | Compounds and Compositions as Tpo Mimetics | IRM LLC (BM) | 2008-08-14 | — | — | US | disclosed |
| US-20080194668-A1 | Compounds and Compositions as Tpo Mimetics | IRM LLC (BM) | 2008-08-14 | — | — | US | disclosed |
| US-20080194668-A1 | Compounds and Compositions as Tpo Mimetics | IRM LLC (BM) | 2008-08-14 | — | — | US | disclosed |
| EP-1915341-A2 | COMPOUNDS AND COMPOSITIONS AS TPO MIMETICS | IRM, LLC (BM) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007022269-A2 | COMPOUNDS AND COMPOSITIONS AS TPO MIMETICS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022269-A2 | COMPOUNDS AND COMPOSITIONS AS TPO MIMETICS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194668-A1 | Compounds and Compositions as Tpo Mimetics | MPL, TPO, THPO | RHEB 1369/4885MPL 1/4885MAPT 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.